Anavex Life Sciences Corp (AVXL)

[McMagyar]

so Anavex has ALREADY PROVED SOC for 25% of the treated AD Population,
and after de-Pooling all the Data, my guess would be..
even those NOT on Mono-Therapy, that 27 out of 27 Experience Benefit to taking A2-73..Thus making SOC for 100% of AD Patients still in study.

9 Month data is still relevant, to some extent..but really what A2-73 seems to prove out, is that Sooner is Better..and that Mono-Therapy with A2-73 may keep and restore a brain to good health..along with perhaps other Vital Organs that are engaged byt Sigma 1 Lignads..

Anavexnow